OptumRx step therapy denied: how to appeal

Quick answer

If OptumRx denied your step therapy override, you can appeal, and the plan must give you its file and the criteria it used. Filing windows by plan type: at least 180 days (employer self-funded plans); at least 180 days (insured and Marketplace plans); 65 days from the notice (Part D); 60 days from the notice (Medicaid managed care). The date printed on your denial notice controls; it can only be later than these floors, never earlier.

Why OptumRx denies step therapy override

OptumRx is UnitedHealth Group's pharmacy benefit manager and administers drug coverage for UHC commercial and Medicare Part D plans, plus many third-party employer groups. The appeal track mirrors UHC procedurally but is filed and decided separately from the medical benefit.

For step therapy override specifically: Step therapy (also called 'fail-first') requires patients to try a plan-preferred medication and demonstrate failure or intolerance before the plan will cover the prescribed drug. Federal and many state laws require plans to allow exception requests when the step is clinically inappropriate.

The law that controls this appeal

Federal and state step-therapy override laws require an exception for contraindication, intolerance, prior failure, or likely ineffectiveness.

At a glance

OptumRx appeals: the rule, the deadline and the next level, by plan type

OptumRx adjudicates the pharmacy benefit for a plan sponsor, so the sponsor's rules govern the appeal: an employer plan (ERISA), an insured or Marketplace plan, Medicare Part D or Medicaid. The denial letter names the plan whose rules apply.

Plan type	Rule that governs	File your appeal within	The plan must answer	If the plan says no again
Employer self-funded plan (ERISA) Most large employers. The employer pays the claims and hires the carrier to administer them; the Summary Plan Description says self-funded or self-insured.	ERISA § 503 (29 U.S.C. § 1133) and the claims-procedure rule, 29 CFR 2560.503-1. Federal external review under 45 CFR 147.136(d) for non-grandfathered plans.	At least 180 days from the adverse benefit determination (29 CFR 2560.503-1(h)(3)(i)).	Urgent care: 72 hours. Pre-service: 30 days. Post-service: 60 days (29 CFR 2560.503-1(i)(2)).	Federal external review by an accredited independent review organization, requested within 4 months of the final internal denial (45 CFR 147.136(d)); then a civil action under ERISA § 502(a). State insurance departments do not regulate self-funded plans; the U.S. Department of Labor does.
Fully insured employer, individual or Marketplace plan The carrier holds the risk and is licensed in your state. Small employers and almost all individual and HealthCare.gov plans.	45 CFR 147.136 (Public Health Service Act § 2719), which applies the 29 CFR 2560.503-1 procedures and adds state external review; state insurance law on top.	At least 180 days from the denial (45 CFR 147.136(b); 29 CFR 2560.503-1(h)(3)(i)).	Urgent care: 72 hours. Pre-service: 30 days. Post-service: 60 days. Prior-authorization decisions by Marketplace issuers from 2026: 72 hours expedited, 7 calendar days standard (CMS-0057-F).	External review through your state's process, or the federal process where the state has none, generally within 4 months of the final internal denial (45 CFR 147.136(c), (d)). The state insurance department and its Consumer Assistance Program take complaints.
Medicare Part D (drug plan or MA-PD) A stand-alone drug plan or the drug benefit inside a Medicare Advantage plan.	42 CFR Part 423, Subpart M; exceptions under 42 CFR 423.578.	65 calendar days from the date on the notice to request a redetermination (42 CFR 423.582, as amended effective 1 January 2025). Formulary, tiering and step-therapy exceptions need the prescriber's supporting statement (§ 423.578).	Redetermination: 7 calendar days standard, 72 hours expedited (42 CFR 423.590). Coverage determinations: 72 hours standard, 24 hours expedited, once the prescriber's statement is received (§§ 423.568, 423.572).	Independent Review Entity reconsideration on your request within 65 days of the redetermination notice (§ 423.600); then ALJ, Council and court.
Medicaid managed care plan A Medicaid plan run by the carrier under a state contract. The card says Medicaid, Medi-Cal, STAR, HealthChoice or your state's programme name.	42 CFR Part 438, Subpart F (plan appeals) and 42 CFR Part 431, Subpart E (state fair hearings).	60 calendar days from the date on the notice of adverse benefit determination to request the plan's appeal (42 CFR 438.402(c)(2)(ii)). State fair hearing: within 120 calendar days of the plan's appeal decision (§ 438.408(f)(2)).	Standard appeal: 30 calendar days. Expedited: 72 hours (42 CFR 438.408(b)).	A state fair hearing after the plan's single level of appeal (§ 438.402(b)); some states add an external medical review. Benefits continue during the appeal if you ask within 10 calendar days of the notice (§ 438.420).

Employer self-funded plan (ERISA)

What you can demand. The plan must give you the claim file, the internal rule or criterion it relied on, and the identity of the reviewer, free of charge, on request (29 CFR 2560.503-1(h)(2)(iii), (m)(8)).

How to open the appeal. Cite ERISA § 503 and 29 CFR 2560.503-1 in the opening paragraph: request the claim file and the specific criteria relied on, and note the 30-day (pre-service), 60-day (post-service) and 72-hour (urgent) decision clocks.

Fully insured employer, individual or Marketplace plan

What you can demand. The plan must give you the claim file, the criteria it applied and any new evidence or rationale before the final decision, free of charge (45 CFR 147.136(b)(2)(ii)(C); 29 CFR 2560.503-1(h)(2)(iii)).

How to open the appeal. Cite 45 CFR 147.136 and 29 CFR 2560.503-1: request the claim file and the criteria, note the decision clocks, and name the state external-review right.

Medicare Part D (drug plan or MA-PD)

What you can demand. The exception turns on the prescriber's statement that the formulary alternative would be less effective or would harm you (42 CFR 423.578(b)(5)).

How to open the appeal. Cite 42 CFR 423.578 and 423.582 and attach the prescriber's supporting statement written to the exception standard.

Medicaid managed care plan

What you can demand. Free copies of the case file, medical records and the criteria used, before and during the appeal (42 CFR 438.406(b)(5)). Children under 21 have EPSDT rights to medically necessary care (42 U.S.C. 1396d(r)(5)).

How to open the appeal. Cite 42 CFR 438.402 and 438.406(b)(5): request the case file and the criteria, ask for continued benefits within 10 days, and reserve the state fair hearing.

Primary sources for this table

Windows are federal floors or the rule as written; the denial notice controls. Reviewed 13 September 2026. General information, not legal advice; Apellica is not a law firm.

What OptumRx denies for step therapy override

The step therapy override services most often denied:

Biologics for rheumatoid arthritis, psoriasis, Crohn's, ulcerative colitis
MS disease-modifying therapies
GLP-1s when a less-effective oral is preferred
Newer migraine therapies (CGRP inhibitors)
Specialty oncology when older regimens are preferred

Why step therapy override claims get denied

A typical OptumRx step therapy override denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:

Patient has not tried and failed the preferred drug
Documentation of prior trial / failure is incomplete
Plan does not recognize prior trial done under previous plan
Contraindication or intolerance not documented in record

The OptumRx appeal process

Appeal levels: Coverage determination / exception request, then plan-level redetermination, then external review (IRO commercial; IRE / MAXIMUS for Part D).

Carrier timing: Standard exception: 72 hours. Expedited: 24 hours. Redetermination filing window: 65 days from the notice for Part D (42 CFR 423.582), at least 180 days for commercial.

Step therapy timing: Standard exception: typically 72 hours. Expedited urgent: 24 hours. Most state step-therapy override laws require response within 72 hours or less.

What we know about OptumRx: Where the medical and pharmacy benefits both touch the same therapy (e.g. provider-administered biologics), we file parallel appeals in both lanes to avoid a procedural gap.

Common OptumRx denial patterns for step therapy override

Separate appeal track from UHC medical. An OptumRx denial is not a UHC medical denial, and vice versa. Filing the wrong appeal track is one of the most common preventable errors. We confirm whether the denial originated at the pharmacy benefit or the medical benefit before filing.
Specialty drug routing through BriovaRx / Optum Specialty. Specialty injectables and infused biologics often route through Optum's specialty pharmacy. Denials at this layer require formulary-exception documentation with clinical rationale, prior-trial data, and (where applicable) FDA-label citation.
Part D coverage determinations. OptumRx-administered Part D plans follow the federal 5-level Part D appeal ladder. The IRE for Part D escalation is MAXIMUS Federal Services. Tiering and formulary exceptions are filed before a coverage-determination challenge.

How to win your OptumRx step therapy override appeal

Strategy for step therapy override: File a step-therapy override request citing one of the standard override grounds: (1) prior trial and failure of the preferred drug, (2) contraindication to the preferred drug, (3) intolerance / adverse reaction, (4) likely-ineffective based on clinical characteristics, or (5) stability on current therapy. Attach prior pharmacy records from any plan to demonstrate prior trials. Many state laws now codify a tight response timeline for step-therapy overrides, cite the applicable statute.

Filed against OptumRx, that strategy rides on this procedural spine:

Procedural-rights anchor. Cite ERISA § 503 and 29 CFR 2560.503-1 in the opening paragraph: request the claim file and the specific criteria relied on, and note the 30-day (pre-service), 60-day (post-service) and 72-hour (urgent) decision clocks. If your OptumRx coverage is a different plan type (Fully insured employer, individual or Marketplace plan, Medicare Part D, Medicaid managed care plan), use that row of the table above instead; the rule and the deadline change with the plan, not the carrier.
Criteria-disclosure demand. OptumRx frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
Controlling-standard citation. Federal and state step-therapy override laws require an exception for contraindication, intolerance, prior failure, or likely ineffectiveness.
Treating-provider attestation. A letter from the treating physician addressing each criterion in OptumRx's own policy language. This is the single strongest evidentiary element.
Requested action. A specific demand to reverse the step therapy override denial and approve the service, not a general "please reconsider."

Documents you'll need for your OptumRx step therapy override appeal

Denial letter
Prescription record from current and prior plans
Prescriber's letter documenting clinical rationale and any prior trials
Documentation of contraindication or intolerance (if applicable)
Relevant lab values or imaging supporting indication

What a step therapy override appeal can recover

Typical recovery for step therapy override cases runs $500 - $30,000+ per month of medication. The exact figure depends on the specific service and your plan's contracted rates.

OptumRx step therapy override appeals: frequently asked questions

Can I get your OptumRx step therapy requirement waived?

Yes, through a step-therapy override request. Federal and many state laws require plans to grant an exception when the required first-line drug is clinically inappropriate for you.

What are the grounds for a step-therapy override?

Prior trial and failure of the preferred drug, a contraindication to it, an intolerance or adverse reaction, a clinical likelihood that it will be ineffective, or current stability on the prescribed therapy. Any one is sufficient.

How fast must OptumRx respond to an override request?

A standard exception is typically decided within 72 hours and an urgent one within 24 hours. Many state step-therapy laws codify a 72-hour-or-less response requirement.

What if my prior drug trial was under a different plan?

Bring it anyway. Pharmacy records from any prior plan can document a prior trial and failure; plans sometimes refuse to recognize outside trials, but the records are strong evidence on appeal.

What Apellica does for OptumRx step therapy override appeals

We file appeals against OptumRx specifically configured to its internal review process. Every step therapy override appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.

Cost: $0 upfront. We work on contingency for OptumRx appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.

Start your OptumRx step therapy override appeal

Submit a 2-minute intake. A senior reviewer responds within one business day with the specific appeal strategy for your case.

Start free appeal review →

OptumRx denied your step therapy override? Here is what to do next